Activation of Mutant Enzyme Function by Proteasome Inhibitors and Treatments that Induce Hsp70

English version České info

Missense mutant proteins, such as those produced in individuals with genetic diseases, are often misfolded and subject to processing by intracellular quality control systems. Previously, we have shown using a yeast system that enzymatic function could be restored to I278T cystathionine β-synthase (CBS), a cause of homocystinuria, by treatments that affect the intracellular chaperone environment. Here, we extend these studies and show that it is possible to restore significant levels of enzyme activity to 17 of 18 (94%) disease causing missense mutations in human cystathionine β-synthase (CBS) expressed in Saccharomyces cerevisiae by exposure to ethanol, proteasome inhibitors, or deletion of the Hsp26 small heat shock protein. All three of these treatments induce Hsp70, which is necessary but not sufficient for rescue. In addition to CBS, these same treatments can rescue disease-causing mutations in human p53 and the methylene tetrahydrofolate reductase gene. These findings do not appear restricted to S. cerevisiae, as proteasome inhibitors can restore significant CBS enzymatic activity to CBS alleles expressed in fibroblasts derived from homocystinuric patients and in a mouse model for homocystinuria that expresses human I278T CBS. These findings suggest that proteasome inhibitors and other Hsp70 inducing agents may be useful in the treatment of a variety of genetic diseases caused by missense mutations.

Vyšlo v časopise: Activation of Mutant Enzyme Function by Proteasome Inhibitors and Treatments that Induce Hsp70. PLoS Genet 6(1): e32767. doi:10.1371/journal.pgen.1000807
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1000807

Souhrn

Zdroje

1. StensonPD

BallEV

MortM

PhillipsAD

ShielJA

2003 Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 21 577 581

2. BrossP

CorydonTJ

AndresenBS

JorgensenMM

BolundL

1999 Protein misfolding and degradation in genetic diseases. Hum Mutat 14 186 198

3. KrugerWD

WangL

JheeKH

SinghRH

ElsasLJ,2nd

2003 Cystathionine beta-synthase deficiency in Georgia (USA): correlation of clinical and biochemical phenotype with genotype. Hum Mutat 22 434 441

4. MuddSH

SkovbyF

LevyHL

PettigrewKD

WilckenB

1985 The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 37 1 31

5. WilckenDE

WilckenB

1997 The natural history of vascular disease in homocystinuria and the effects of treatment. Journal of Inherited Metabolic Disease 20 295 300

6. YapS

NaughtenER

WilckenB

WilckenDE

BoersGH

2000 Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy. Semin Thromb Hemost 26 335 340

7. YapS

BoersGH

WilckenB

WilckenDE

BrentonDP

2001 Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 21 2080 2085

8. GuptaS

KühnischJ

MustafaA

LhotakS

SchlachtermanA

2009 Mouse models of cystathionine β-synthase deficiency reveal significant threshold effects of hyperhomocysteinemia. FASEB J 23 883 893

9. VarleyJM

2003 Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21 313 320

10. GonzalezKD

NoltnerKA

BuzinCH

GuD

Wen-FongCY

2009 Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations. J Clin Oncol 27 1250 1256

11. EsrigD

SpruckCH3rd

NicholsPW

ChaiwunB

StevenK

1993 p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Amer J Path 143 1389 1397

12. Cooper EVBDN

StensonPD

PhillipsAD

HowellsK

MortME

2009 The human gene mutation database at the institute of medical genetics at Cardiff.

13. GoyetteP

FrosstP

RosenblattDS

RozenR

1995 Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Amer J Hum Genet 56 1052 1059

14. SinghLR

KrugerWD

2009 Functional rescue of mutant human cystathionine β-synthase by manipulation of Hsp26 and Hsp70 levels in Saccharomyces cerevisiae. J Biol Chem 284 4238 4245

15. YoungJC

AgasheVR

SiegersK

HartlFU

2004 Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol 5 781 791

16. HartlFU

Hayer-HartlM

2002 Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295 1852 1858

17. KrausJP

JanosikM

KozichV

MandellR

ShihV

1999 Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat 13 362 375

18. LeeDH

GoldbergAL

1998 Proteasome inhibitors cause induction of heat shock proteins and trehalose, which together confer thermotolerance in Saccharomyces cerevisiae. Mol Cell Biol 18 30 38

19. KimD

LiGC

1999 Proteasome inhibitors lactacystin and MG132 inhibit the dephosphorylation of HSF1 after heat shock and suppress thermal induction of heat shock gene expression. Biochem Biophys Res Com 264 352 358

20. OrlowskiRZ

KuhnDJ

2008 Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14 1649 1657

21. FlamanJM

FrebourgT

MoreauV

CharbonnierF

MartinC

1995 A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A 92 3963 3967

22. ShanX

WangL

HoffmasterR

KrugerWD

1999 Functional characterization of human methylenetetrahydrofolate reductase in Saccharomyces cerevisiae. J Biol Chem 274 32613 32618

23. WangL

ChenX

TangB

HuaX

Klein-SzantoA

2005 Expression of mutant human cystathionine beta-synthase rescues neonatal lethality but not homocystinuria in a mouse model. Hum Mol Genet 14 2201 2208

24. ChenX

WangL

FazlievaR

KrugerWD

2006 Contrasting behaviors of mutant cystathionine beta-synthase enzymes associated with pyridoxine response. Hum Mutat 27 474 482

25. DePristoMA

WeinreichDM

HartlDL

2005 Missense meanderings in sequence space: a biophysical view of protein evolution. Nat Rev Genet 6 678 687

26. MeierM

JanosikM

KeryV

KrausJP

BurkhardP

2001 Structure of human cystathionine beta-synthase: a unique pyridoxal 5′-phosphate-dependent heme protein. Embo J 20 3910 3916

27. MuTW

FowlerDM

KellyJW

2008 Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol 6 e26 doi:10.1371/journal.pbio.0060026

28. KieranD

KalmarB

DickJR

Riddoch-ContrerasJ

BurnstockG

2004 Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nature Med 10 402 405

29. GilardiniA

MarmiroliP

CavalettiG

2008 Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity? Curr Med Chem 15 3025 3035

30. JagannathS

VijR

StewartK

SomloA

JackubowiakA

2009 Final resutls of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma. 2009 ASCO Annual Meeting Orlando Fl J. Clin Oncol 15S (abstr 8504)

31. SolitDB

IvySP

KopilC

SikorskiR

MorrisMJ

2007 Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13 1775 1782

32. CudkowiczME

ShefnerJM

SimpsonE

GrassoD

YuH

2008 Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle and Nerve 38 837 844

33. SoussiT

WimanKG

2007 Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12 303 312

34. BykovVJ

IssaevaN

ShilovA

HultcrantzM

PugachevaE

2002 Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8 282 288

35. BykovVJ

SelivanovaG

WimanKG

2003 Small molecules that reactivate mutant p53. European Journal of Cancer 39 1828 1834

36. AdamsJ

PalombellaVJ

SausvilleEA

JohnsonJ

DestreeA

1999 Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research 59 2615 2622

37. KrugerWD

1994 A yeast system for expression of human cystathionine beta-synthase: structual and functional conservation of the human and yeast genes. Proc Natl Acad Sci USA 91 6614 6618

38. KrugerWD

CoxDR

1995 A yeast assay for functional detection of mutations in the human cystathionine beta-synthase gene. Hum Mol Genet 4 1155 1161

39. ShanX

KrugerWD

1998 Correction of disease-causing CBS mutations in yeast. Nat Genet 19 91 93

40. TangB

LiYN

KrugerWD

2000 Defects in methylthioadenosine phosphorylase are associated with but not responsible for methionine-dependent tumor cell growth. Cancer Res 60 5543 5547

41. TangB

KadariyaY

MurphyME

KrugerWD

2006 The methionine salvage pathway compound 4-methylthio-2-oxobutanate causes apoptosis independent of down-regulation of ornithine decarboxylase. Biochem Pharmacol 72 806 815

42. MoatSJ

BaoL

FowlerB

BonhamJR

WalterJH

2004 The molecular basis of cystathionine beta-synthase (CBS) deficiency in UK and US patients with homocystinuria. Hum Mutat 23 206

43. de FranchisR

KrausE

KozichV

SebastioG

KrausJP

1999 Four novel mutations in the cystathionine beta-synthase gene: effect of a second linked mutation on the severity of the homocystinuric phenotype. Hum Mutat 13 453 457

44. HuFL

GuZ

KozichV

KrausJP

RameshV

1993 Molecular basis of cystathionine beta-synthase deficiency in pyridoxine responsive and nonresponsive homocystinuria. Hum Mol Genet 2 1857 1860

45. ShanX

DunbrackRLJr

ChristopherSA

KrugerWD

2001 Mutations in the regulatory domain of cystathionine beta synthase can functionally suppress patient-derived mutations in cis. Hum Mol Genet 10 635 643

46. WangL

JheeKH

HuaX

DiBelloPM

JacobsenDW

2004 Modulation of cystathionine beta-synthase level regulates total serum homocysteine in mice. Circ Res 94 1318 1324

47. GuptaS

WangL

HuaX

KrijtJ

KozichV

2008 Cystathionine β-synthase p.S466L mutation causes hyperhomocysteinemia in mice. Hum Mutat 29 1048 1054